The present work aimed to develop Nanostructured Lipid Carrier Based Hydrogel for the treatment of psoriasis, delivered as a topical application on to the skin. Nanostructured Lipid carrier based Hydrogel loaded with methotrexate is a new technique for topical administration for psoriasis. Methotrexate loaded NLC's were prepared by a hot homogenization method using high-pressure homogenizer. Stearic acid and oleic acid were selected as the solid lipid and liquid lipid, respectively. Tween 80 used as a surfactant. The developed lipid formulations were incorporated in 1% Carbopol 934 gel medium to maintain the topical application consistency. Fourier-Transform Infrared Spectroscopy was employed to identify their functional groups. Differential Scanning Calorimetry was employed to determine its melting point. The particle size, zeta potential, polydispersity index for the MTX-NLC were found to be 239.12±3.65nm, -24.61mV and 0.245 to 0.517. Scanning electronic microscopy studies will reveal the surface morphology of the nanoparticles. The pH of the drug-loaded formulation was in the range of 4.93 to 5.83. Spreadability was in the range of 3.01±0.59cm to 8.13±0.34cm. Viscosity at 25±2oC was 67325 cps.  In vitro studies suggest that initial release rate was observed within first 4 hrs and amount of drug release was 35 to 47± 3.61%, fast and sustained release rate reached by 24th hr and release rate of the drug was 72%.  The stability studies reported that the formulation was stable for 30 days after the incorporation of the drug, and there was no drug degradation or decomposition and no change in physical appearance. Hence, results indicate the sustain release activity of MTX-NLC Hydrogels, which could help in preventing the cell division and proliferation of cell acting as a major barrier in the topical application of psoriasis.

Objective:The objective of the present research was to develop fixed-dose combinations for the treatment of dyslipidemia, associated with type-II diabetes mellitus for improvement of glucose tolerance. Methods:Multiple unit pellet systems (MUPSs) consisting immediate release atorvastatin calcium pellets and sustained release glibenclamide were formulated by spheronization technique. The characterization of formulated pellets was done by Fourier transform infrared (FT-IR) and differential scanning calorimetry (DSC) studies, and formulated pellets were evaluated for solubility, viscosity, pH, and in vitro studies.Results: From FT-IR and DSC studies, it was confirmed that no chemical interaction existed between the drug and the natural polymers used. Solubility of glibenclamide was found to be 4.38 and 18.24 and atorvastatin calcium was found to be 6.84, 214.67, and 287.43 g/L. The viscosity of 1% w/v of locust bean gum, guar gum, and ghatti gum was found to be 169 cP, 124 cP, and 31 cP in distilled water. The pH of locust bean gum, guar gum, and gum ghatti solutions was found to be 5. 6±0.49, 5.2±0.27, and 4.7±0.51. The in vitro studies suggested that glibenclamide pellets had shown a sustained release till 12 h, while atorvastatin calcium had shown immediate release of drug due to rapid disintegration of pellets. Conclusion:Thus, MUPS can be considered as an alternative approach to treat diabetes induced dyslipidemia.